COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06ALE
|
|||
Drug Name |
IFX-1
|
|||
Synonyms |
IFX-1 mab
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2/3 | [1] | |
Therapeutic Class |
Antiviral Agents
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN complement C5 alpha (C5A) | Target Info | Inhibitor | [2] |
IFX-1, a first-in-class monoclonal anti-human complement factor C5a antibody, highly and effectively blocks the biological activity of C5a to control the inflammatory response driven tissue and organ damage in patients with SARS-CoV-2. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04333420) Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health. | |||
2 | 03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRxs anti-C5a Technology |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.